



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Ubamatamab

Cat. No.:	HY-P99539
CAS No.:	2305629-50-7
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity <sup>[1]</sup> .	
<b>In Vitro</b>	Ubamatamab (REGN4018; 0.1 pM-10 nM; 48 hours) induces human T cells and cynomolgus T cells to kill OVCAR-3 cells (EC50, 13.6 pM and 30.6 pM, respectively) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <sup>[1]</sup>	
	Cell Line:	OVCAR-3 cells
	Concentration:	0.1 pM-10 nM
	Incubation Time:	48 hours
	Result:	Induced human T cells and cynomolgus T cells to kill OVCAR-3 cells.
<b>In Vivo</b>	Ubamatamab (REGN4018; 0.01-0.5 mg/kg; i.p; on days 6, 10, 13, 16, and 21) potentially inhibits growth of intraperitoneal ovarian tumors <sup>[1]</sup> . Ubamatamab (REGN4018; 0.01-1 mg/kg; i.p; once a week; total of five doses) shows minimal and transient increases in serum cytokines and C-reactive protein, with no overt toxicity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	NOD SCID gamma (NSG) mice injected with OVCAR-3/Luc cells <sup>[1]</sup>
	Dosage:	0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg
	Administration:	i.p; on days 6, 10, 13, 16, and 21
	Result:	Significantly reduced tumor burden, and did not result in any changes in weight.
	Animal Model:	Cynomolgus monkeys
	Dosage:	0.01, 0.1, or 1 mg/kg

---

Administration:	i.p; once a week; total of five doses
Result:	Showed minimal and transient increases in serum cytokines and C-reactive protein.

---

## REFERENCES

---

[1]. Alison Crawford, et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA